Atypical fractures in pediatric patients with osteogenesis imperfect treated with zoledronic acid

2019 ◽  
Author(s):  
Bremer Alheli Lucia ◽  
Patricia Clark
Keyword(s):  
Zoledronic Acid ◽  
Pediatric Patients ◽  
Atypical Fractures

scholarly journals Safety & Efficacy of Cyclic Zoledronic Acid Therapy on Pediatric Secondary Osteoporosis

2015 ◽  
Vol 8 (8) ◽  
pp. 20
Author(s):  
Abdulmoein E. Al-Agha ◽  
Talal A. Shaikhain ◽  
Abdullah A. Ashour
Keyword(s):  
Zoledronic Acid ◽  
Children And Adolescents ◽  
Pediatric Patients ◽  
Systemic Disease ◽  
Laboratory Data ◽  
University Hospital ◽  
Secondary Osteoporosis ◽  
Fracture Rate ◽  
Acid Therapy ◽  
Positive Effects

<p class="NormalWeb"><strong>BACKGROUND/AIM:</strong> Osteoporosis is a systemic disease characterized by decreased bone density and increased tendency to develop fractures. Osteoporosis in children and adolescents is a rare disease usually secondary to Medical conditions or medications given to children. The condition affects normal bone growth and development and carries with it multiple morbidities (physical and psychological) if not corrected promptly. This study aims to share our experience with Zoledronic Acid Therapy in Pediatric patients with secondary osteoporosis.</p><p class="NormalWeb"><strong>METHOD:</strong> A retrospective study which included 46 patients aged 3 to 18 years. All patients received specific doses of Zoledronic acid and were followed up at King Abdulaziz University Hospital (KAUH) in Jeddah, Saudi Arabia. Clinical and laboratory data were collected for each patient from their files. Adverse events were also recorded.</p><p class="NormalWeb"><strong>RESULTS:</strong> The use of Zoledronic Acid in children and adolescents appears to be statically significant reduce fracture rate (p=0.005), bone turnover markers (Osteocalcin p= 0.003, CTX p= 0.008) and pain frequency in symptomatic individuals (p=0.000). Careful selection of cases is required to provide maximum benefits compared to risks associated with therapy.</p><p class="NormalWeb"><strong>CONCLUSION:</strong> This study demonstrates that Zoledronic acid has positive effects on clinical outcome and bone marker level as well as quality of life for Pediatric patients with Osteoporosis and their families, with no long-term side effects.</p>

Craniofacial consequences of high-dose zoledronic acid injections in onco-pediatric patients

2013 ◽  
Author(s):  
Frederic Lezot ◽  
Julie Chesneau ◽  
Severine Battaglia ◽  
Regis Brion ◽  
Jean-Christophe Farges ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Pediatric Patients ◽  
High Dose

scholarly journals Biological Effects of Anti-RANKL Antibody and Zoledronic Acid on Growth and Tooth Eruption in Growing Mice

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Motoki Isawa ◽  
Akiko Karakawa ◽  
Nobuhiro Sakai ◽  
Saki Nishina ◽  
Miku Kuritani ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Osteoblast Differentiation ◽  
Pediatric Patients ◽  
Root Formation ◽  
Biological Effects ◽  
Normal Growth ◽  
Bone Diseases ◽  
Bone Volume ◽  
Tooth Eruption ◽  
Tooth Root

AbstractThe anti-bone resorptive drugs denosumab, an anti-human-RANKL antibody, and zoledronic acid (ZOL), a nitrogen-containing bisphosphonate, have recently been applied for treatment of pediatric patients with bone diseases, though details regarding their effects in growing children have yet to be fully elucidated. In the present study, we administered these anti-resorptive drugs to mice from the age of 1 week and continued once-weekly injections for a total of 7 times. Mice that received the anti-RANKL antibody displayed normal growth and tooth eruption, though osteopetrotic bone volume gain in long and alveolar bones was noted, while there were nearly no osteoclasts and a normal of number osteoblasts observed. In contrast, ZOL significantly delayed body growth, tooth root formation, and tooth eruption, with increased osteoclast and decreased osteoblast numbers. These findings suggest regulation of tooth eruption via osteoblast differentiation by some types of anti-resorptive drugs.

Craniofacial consequences of high dose zoledronic acid injections in onco-pediatric patients

2013 ◽  
Author(s):  
Lezot Frederic ◽  
Chesneau Julie ◽  
Battaglia Severine ◽  
Brion Regis ◽  
Farges Jean-Christophe ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Pediatric Patients ◽  
High Dose

Preclinical evidence of potential craniofacial adverse effect of zoledronic acid in pediatric patients with bone malignancies

Bone ◽  
2014 ◽  
Vol 68 ◽  
pp. 146-152 ◽  
Author(s):  
Frédéric Lézot ◽  
Julie Chesneau ◽  
Séverine Battaglia ◽  
Régis Brion ◽  
Beatriz Castaneda ◽  
...  
Keyword(s):  
Adverse Effect ◽  
Zoledronic Acid ◽  
Pediatric Patients

Audiology Service Models in a Family Physician Practice Setting

2010 ◽  
Vol 6 (1) ◽  
pp. 24-32 ◽  
Author(s):  
Sridhar Krishnamurti
Keyword(s):  
Pediatric Patients ◽  
Practice Patterns ◽  
Healthcare Delivery ◽  
Direct Consequence ◽  
Direct Access ◽  
Practice Setting ◽  
Pediatric Populations ◽  
Family Practice Physicians ◽  
Primary Focus ◽  
Balance Problems

This article illustrates the potential of placing audiology services in a family physician’s practice setting to increase referrals of geriatric and pediatric patients to audiologists. The primary focus of family practice physicians is the diagnosis/intervention of critical systemic disorders (e.g., cardiovascular disease, diabetes, cancer). Hence concurrent hearing/balance disorders are likely to be overshadowed in such patients. If audiologists get referrals from these physicians and have direct access to diagnose and manage concurrent hearing/balance problems in these patients, successful audiology practice patterns will emerge, and there will be increased visibility and profitability of audiological services. As a direct consequence, audiological services will move into the mainstream of healthcare delivery, and the profession of audiology will move further towards its goals of early detection and intervention for hearing and balance problems in geriatric and pediatric populations.

Sign in / Sign up

Export Citation Format

Share Document